Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice

Circulation Journal

Volumn 69, Issue 12, 2005, Pages 1543-1546

  Okabe, Taka Aki ^a   Kishimoto, Chiharu ^a   Shimada, Kana ^a   Murayama, Toshinori ^a   Yokode, Masayuki ^a   Kita, Toru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; F(ab')2 fragments; Fc portion; Immunoglobulin

Indexed keywords

CHOLESTEROL; GAMMA VENIN; IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL INTAKE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFICACY; HEART PROTECTION; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; NONHUMAN; RAT; SPECIES COMPARISON;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MICE, KNOCKOUT; TREATMENT OUTCOME;

EID: 28544449912     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1543     Document Type: Article

References (18)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115 - 126.
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876 - 1890.
3. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
4. Kawashiri MA, Higashikata T, Takata M, Katsuda S, Miwa K, Nohara A, et al. Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis. Circ J 2005; 69: 746 - 751.
5. Nasuno A, Matsubara T, Hori T, Higuchi K, Tsuchida K, Mezaki T, et al. Acute pulmonary thromboembolism induced by prophylactic heparin use and a heparin-coated catheter: A case of heparin-induced thrombocytopenia and thrombosis syndrome. Circ J 2003; 67: 96 - 98.
6. Espinola-Klein C, Rupperecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Impact of infectious burden on extent and longterm prognosis of atherosclerosis. Circulation 2002; 105: 15 - 21.
7. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000; 20: 1536 - 1542.
8. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomized, multicentre trial. Lancet 2002; 359: 23 - 29.
9. Kazatchkine MD, Kaveri SV. Immunodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747 - 755.
10. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: Concomitant suppression of the expression of dendritic cells. Circ Res 2001; 89: 540 - 546.
11. Shioji K, Yuan Z, Kita T, Kishimoto C. Immunoglobulin treatment suppressed adoptively transferred autoimmune myocarditis in severe combined immunodeficient mice. Am J Physiol 2004; 287: H2619-H2625.
12. Shioji K, Matsuura Y, Iwase T, Kitaguchi S, Nakamura H, Yodoi J, et al. Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: A case report. Circ J 2002; 66: 977 - 980.
13. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein Edeficient mice via the Fc portion. Am J Physiol 2003; 285: H899-H906.
14. Murayama T, Yokode M, Kataoka H, Imabayashi T, Yoshida H, Sano H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but dose not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 1999; 99: 1740 - 1746.
15. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102: 910 - 918.
16. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484 - 486.
17. Kawashiri MA, Higashikata T, Noharara A, Kobayashi J, Inazu A, Koizumi J, et al. Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 2005; 69: 515 - 520.
18. Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ J 2004; 68: 1061 - 1066.